Day One Biopharmaceuticals
Tracked across 2 events · 63 articles · First seen Feb 13, 2026 · Last active Mar 26, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Day One Biopharmaceuticals, Inc. is being acquired by Laboratoires Servier for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. This acquisition provides a unique opportunity to extend the reach of its science and lead program in pediatric low-grade glioma, benefiting its mission to bring medicines to patients with life-threatening diseases.
Mar 06, 2026 · 8 articles
Business
Day One Biopharmaceuticals is being investigated by Monteverde & Associates PC regarding its sale to Servier Pharmaceuticals LLC for $21.50 per share, potentially facing a class action lawsuit.
Feb 13, 2026 · 55 articles
Fenwick & West
legal counsel
↔
Day One Biopharmaceuticals
Fenwick & West LLP is serving as legal counsel to Day One Biopharmaceuticals, In
Tarkus
CEO
↔
Day One Biopharmaceuticals
Tarkus is the chief executive officer of Day One Biopharmaceuticals, Inc.
Centerview Partners
financial advisor
↔
Day One Biopharmaceuticals
Centerview Partners LLC is the exclusive financial advisor to Day One Biopharmac
NEWSDESK
Track Day One Biopharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard